Summary of Study ST003237

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002012. The data can be accessed directly via it's Project DOI: 10.21228/M8J82C This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003237
Study TitlePlasma metabolomics of patients diagnosed with Alzheimer's Disease under Acetylcholinesterase Inhibitors treatment
Study TypeUntargeted Lipidomics Analysis
Study SummaryAlzheimer’s Disease (AD) is a fatal neurodegenerative disorder characterized by progressive memory loss, loss of cognitive capacity, mood swings, communication and rationality impairment and eventual loss of independent living. There is still no cure for this disease, but some medicine can delay the progression of symptoms and improve patients’ life quality by acting in the reduction of symptom severity. Acetylcholinesterase inhibitors (AChI) are the main class of drug employed for this. In this context, this research has a goal of evaluating the metabolomic and lipidomic profile of sanguine plasma of patients diagnosed with AD before and after the use of AChI to elucidate metabolic alterations that can assist the diagnosis and contribute to the literature. The Principal Component Analysis revealed that the posterior analysis did not present instrumental biases. As a result, after assessing metabolic pathways and putatively identified, statistically significant metabolites, it was possible to observe that some groups of metabolites, such as fatty acids and aminoacids, were present both in our data and in literature. Some other pathways, such as the biosynthesis of nitrogen and the biosynthesis of arginine, are also of interest for research purposes.
Institute
University of Campinas
DepartmentInstitute of Chemistry
LaboratoryLaboratory of Bioanalytics and Integated Omics (LaBIOmics)
Last NameMarques
First NameMariana
AddressRua Josué de Castro, s/n
Emailmari31marques@gmail.com
Phone+55 19 35213038
Submit Date2024-05-23
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2025-06-24
Release Version1
Mariana Marques Mariana Marques
https://dx.doi.org/10.21228/M8J82C
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR002012
Project DOI:doi: 10.21228/M8J82C
Project Title:Plasma metabolomics of patients diagnosed with Alzheimer's Disease under Acetylcholinesterase Inhibitors treatment
Project Type:Untargeted Lipidomics
Project Summary:Alzheimer’s Disease (AD) is a fatal neurodegenerative disorder characterized by progressive memory loss, loss of cognitive capacity, mood swings, communication and rationality impairment and eventual loss of independent living. There is still no cure for this disease, but some medicine can delay the progression of symptoms and improve patients’ life quality by acting in the reduction of symptom severity. Acetylcholinesterase inhibitors (AChI) are the main class of drug employed for this. In this context, this research has a goal of evaluating the metabolomic and lipidomic profile of sanguine plasma of patients diagnosed with AD before and after the use of AChI to elucidate metabolic alterations that can assist the diagnosis and contribute to the literature.
Institute:State University of Campinas (UNICAMP)
Department:Institute of Chemistry
Laboratory:Laboratory of Bioanalytics and Integated Omics (LaBIOmics)
Last Name:Marques
First Name:Mariana
Address:Rua Josué de Castro, s/n, Campinas, São Paulo, 13083-862, Brazil
Email:mari31marques@gmail.com
Phone:+55 19 35213038
Funding Source:Conselho Nacional de Desenvolvimento Científico e Tecnólogico
Contributors:Alessandra Sussulini, Leda Leme Talib, Wagner Farid Gattaz

Subject:

Subject ID:SU003356
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Age Or Age Range:68-82
Gender:Male and female
Human Medications:AcetylCholinesterase Inhibitor
Species Group:Mammals

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id AChI dosage Sample source
SA353238AD-190mg Plasma
SA353239AD-170mg Plasma
SA353240AD-160mg Plasma
SA353241AD-150mg Plasma
SA353242AD-200mg Plasma
SA353243AD-210mg Plasma
SA353244AD-010mg Plasma
SA353245AD-020mg Plasma
SA353246AD-230mg Plasma
SA353247AD-220mg Plasma
SA353248AD-140mg Plasma
SA353249AD-180mg Plasma
SA353250AD-060mg Plasma
SA353251AD-070mg Plasma
SA353252AD-050mg Plasma
SA353253AD-130mg Plasma
SA353254AD-030mg Plasma
SA353255AD-080mg Plasma
SA353256AD-040mg Plasma
SA353257AD-120mg Plasma
SA353258AD-090mg Plasma
SA353259AD-110mg Plasma
SA353260AD-100mg Plasma
SA353261AC2-0710mg Plasma
SA353262AC2-0810mg Plasma
SA353263AC2-1010mg Plasma
SA353264AC2-1110mg Plasma
SA353265AC2-0910mg Plasma
SA353266AC2-0510mg Plasma
SA353267AC2-1210mg Plasma
SA353268AC2-0110mg Plasma
SA353269AC2-0310mg Plasma
SA353270AC2-0410mg Plasma
SA353271AC2-0610mg Plasma
SA353272AC2-0210mg Plasma
SA353273AC2-2010mg Plasma
SA353274AC2-2110mg Plasma
SA353275AC2-2210mg Plasma
SA353276AC2-2310mg Plasma
SA353277AC2-1910mg Plasma
SA353278AC2-1810mg Plasma
SA353279AC2-1410mg Plasma
SA353280AC2-1510mg Plasma
SA353281AC2-1610mg Plasma
SA353282AC2-1710mg Plasma
SA353283AC2-1310mg Plasma
SA353284AC1-195mg Plasma
SA353285AC1-075mg Plasma
SA353286AC1-085mg Plasma
SA353287AC1-095mg Plasma
SA353288AC1-105mg Plasma
SA353289AC1-065mg Plasma
SA353290AC1-235mg Plasma
SA353291AC1-015mg Plasma
SA353292AC1-025mg Plasma
SA353293AC1-035mg Plasma
SA353294AC1-045mg Plasma
SA353295AC1-115mg Plasma
SA353296AC1-055mg Plasma
SA353297AC1-185mg Plasma
SA353298AC1-215mg Plasma
SA353299AC1-225mg Plasma
SA353300AC1-125mg Plasma
SA353301AC1-175mg Plasma
SA353302AC1-205mg Plasma
SA353303AC1-135mg Plasma
SA353304AC1-165mg Plasma
SA353305AC1-145mg Plasma
SA353306AC1-155mg Plasma
SA353307QCTOTAL11Non applicable Plasma(Pooled)
SA353308QCTOTAL10Non applicable Plasma(Pooled)
SA353309QCTOTAL12Non applicable Plasma(Pooled)
SA353310QCTOTAL14Non applicable Plasma(Pooled)
SA353311QCTOTAL09Non applicable Plasma(Pooled)
SA353312QCTOTAL13Non applicable Plasma(Pooled)
SA353313QCTOTAL03Non applicable Plasma(Pooled)
SA353314QCTOTAL02Non applicable Plasma(Pooled)
SA353315QCTOTAL01Non applicable Plasma(Pooled)
SA353316QCTOTAL04Non applicable Plasma(Pooled)
SA353317QCTOTAL05Non applicable Plasma(Pooled)
SA353318QCTOTAL07Non applicable Plasma(Pooled)
SA353319QCTOTAL06Non applicable Plasma(Pooled)
SA353320QCTOTAL08Non applicable Plasma(Pooled)
Showing results 1 to 83 of 83

Collection:

Collection ID:CO003349
Collection Summary:The patients for this study were recruited in the ambulatory of Geriatric research of the Laboratory of Neurosciences in the Faculty of Medical Sciences of the University of São Paulo (USP). 40 mL of blood were collected in four 10 mL tubes containing sodium citrate 0.106 mol/L as anticlotting agent. To each tube 1 mL of ACD-NH was added. The tubes were homogenized and centrifuged for 15 minutes at 1600 rpm, 20 ºC. Following this, the supernatant was transferred to a 50 mL Falcon type tube and the pH was adjusted using ACD-NH to 6.5. The plasma was transferred to 4 polystyrene tubes and centrifuged during 10 minutes at 2400 rpm, 20ºC. The supernatant was removed by inversion. Plasma aliquots were storaged at 80 ºC until further analysis.
Sample Type:Blood (plasma)
Collection Frequency:Every 3 months
Storage Conditions:-80℃
Collection Vials:10 mL containing sodium citrate 0.106 mol/L
Storage Vials:polystyrene tubes
Additives:Sodium citrate, ACD-NH

Treatment:

Treatment ID:TR003365
Treatment Summary:The patients diagnosed with Alzheimer's Disease were subjected to Acetylcholinesterase Inihibitors treatment with a starting dose of 5mg for 3 months and 10mg for three more months

Sample Preparation:

Sampleprep ID:SP003363
Sampleprep Summary:For this study the extraction method used was Simplex. Briefly, 40 µL of plasma samples were incubated with 300 µL of cold methanol and 1 mL of MTBE (Methyl tert-butyl ether), followed by the addition of 250 µL of a 0.1% (m/v) ammonium acetate solution to induce phase separation. Bothe the apolar phase containing lipids and the polar phase were separated and dried in a vacuum concentrator (SpeedVac) and stored at -80 °C until further analysis.
Sampleprep Protocol Filename:Sample_Preparation.pdf
Processing Storage Conditions:On ice
Extraction Method:MTBE Simplex (Coman et al, 2016)
Extract Storage:-80℃

Chromatography:

Chromatography ID:CH004011
Methods Filename:LC-MS_lipidomics.pdf
Instrument Name:Thermo Dionex Ultimate 3000
Column Name:Supelco Titan C18 (1.9 μm, 2.1 x 100 mm)
Column Temperature:45
Flow Gradient:The elution gradient started with 40% B from minutes 0-2, 50% B from minutes 3-6, 70% Bfrom minutes 6.1-8, 100% B from minutes 9-11, and from minutes 12-14 the column was stabilized forthe following run
Flow Rate:0.250 mL/min
Injection Temperature:10
Sample Injection:5 uL
Solvent A:40% acetonitrile/60% water; 10 mM ammonium acetate
Solvent B:10% acetonitrile/90% isopropanol;10 mM ammonium acetate
Analytical Time:12 minutes
Capillary Voltage:3.5 V
Chromatography Type:Reversed phase

Analysis:

Analysis ID:AN005301
Analysis Type:MS
Acquisition Date:10/31/2023
Data Format:.raw
Chromatography ID:CH004011
Has Mz:1
Has Rt:1
Rt Units:Minutes
Results File:ST003237_AN005301_Results.txt
Units:Peak Area
  
Analysis ID:AN005302
Analysis Type:MS
Acquisition Date:10/31/2023
Data Format:.raw
Chromatography ID:CH004011
Has Mz:1
Has Rt:1
Rt Units:Minutes
Results File:ST003237_AN005302_Results.txt
Units:Peak Area
  logo